

Protocol

This trial protocol has been provided by the authors to give readers additional information about their work.

Protocol for: Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. *N Engl J Med* 2011;365:725-33. DOI: 10.1056/NEJMoa1103849.

University of Pennsylvania

Title:

***PILOT STUDY OF REDIRECTED AUTOLOGOUS T CELLS ENGINEERED TO
CONTAIN ANTI-CD19 ATTACHED TO TCR ζ AND 4-1BB SIGNALING
DOMAINS IN PATIENTS WITH CHEMOTHERAPY RESISTANT OR
REFRACTORY CD19+ LEUKEMIA AND LYMPHOMA***

Principal Investigator

*David Porter, M.D.
Department of Medicine
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania 19104*

Co-Investigators

*Adam Bagg, MD
Bruce Levine, PhD
Stephen Schuster, MD
Sunita Nasta, MD
Selina Luger, MD
Stephen Goldstein, MD
Noelle Frey, MD
Alison Loren, MD, MSCE
Donald Tsai, MD, PhD
Daniel Vogl, MD
Elizabeth Hexner, MD*

Regulatory Sponsor:

*Carl June, M.D.
Department of Pathology and Laboratory Medicine
University of Pennsylvania School of Medicine
Room 553 BRB II/II,
421 Curie Blvd
Philadelphia, PA 19104-6160
215-573-5745*

Funding Sponsor:

*Alliance for Cancer Gene Therapy
96 Cummings Point Road
Stamford, CT 06902
203 348 8000*

Study Product:

CD19 redirected autologous T cells (CART-19-T Cells)

Protocol Number:

805313

IND Number:

BB-IND 13960

Date:

Amended: June 18, 2009

Administrative Change: In response to FDA/IRB/CTSRMC comments

CONFIDENTIAL

This document is confidential and the property of the University of Pennsylvania. No part

STUDY TEAM

Clinical Trial Site - University of Pennsylvania

Principal Investigator

David Porter, MD

Clinical Team

Steven Goldstein, MD
Donald Tsai, MD, PhD
Stephen Schuster, MD
Selina Luger, MD
Sunita Nasta, MD
Alison Loren, MD, MSCE
Alexander Perl, MD
Noelle Frey, MD
Daniel Vogl, MD
Elizabeth Hexner, MD

Laboratory Team

Adam Bagg, MD
Gwen Binder, PhD
Stephan Grupp, MD, PhD
Jean Boyer, PhD
Michael Milone, MD, PhD
Carmine Carpenito, PhD
Michael Kalos, PhD

Medical Advisor

Edward Stadtmauer, MD

Statistical Support

Wei-Ting Hwang, Ph.D..

Monitors

Tina Lowther, C.I.P., C.R.C.
Elizabeth Veloso, JD, BSN

Quality Assurance for Manufacturing

To be chosen

Sponsor Cell Manufacturing – University of Pennsylvania

Donald Siegel, MD, PhD, Medical Director
Bruce Levine, PhD, Laboratory Director

Sponsor Vector Manufacturing – Lentigen Corporation

Boro Dropulic, PhD

Table of Contents

LIST OF ABBREVIATIONS	V
STUDY SUMMARY AND STUDY SCHEMA	1
1 INTRODUCTION.....	4
1.1 BACKGROUND.....	4
1.2 INVESTIGATIONAL AGENT	7
1.3 PRECLINICAL DATA.....	9
1.4 CLINICAL DATA TO DATE.....	14
1.5 DOSE RATIONALE AND RISK/BENEFITS.....	16
2 STUDY OBJECTIVES	18
3 STUDY DESIGN.....	18
3.1 GENERAL DESIGN.....	18
3.2 PRIMARY STUDY ENDPOINTS	20
3.3 SECONDARY STUDY ENDPOINTS	20
4 SUBJECT SELECTION AND WITHDRAWAL.....	21
4.1 INCLUSION CRITERIA.....	21
4.2 EXCLUSION CRITERIA.....	22
4.3 SUBJECT RECRUITMENT AND SCREENING.....	22
4.4 EARLY WITHDRAWAL OF SUBJECTS.....	23
4.4.1 <i>When and How to Withdraw Subjects.....</i>	<i>23</i>
4.4.2 <i>Data Collection and Follow-up for Withdrawn Subjects.....</i>	<i>24</i>
5 STUDY DRUG	24
5.1 DESCRIPTION.....	24
5.2 TREATMENT REGIMEN.....	25
5.2.1 <i>Patients 1-5</i>	<i>25</i>
5.2.2 <i>Patients 6-10</i>	<i>25</i>
5.3 PREPARATION AND ADMINISTRATION OF STUDY DRUG.....	25
5.4 SUBJECT COMPLIANCE MONITORING	26
5.5 PRIOR AND CONCOMITANT THERAPY	27
5.6 PACKAGING.....	27
5.7 RECEIVING, STORAGE, DISPENSING AND RETURN	27
5.7.1 <i>Receipt of Drug Supplies.....</i>	<i>27</i>
5.7.2 <i>Storage</i>	<i>27</i>
5.7.3 <i>Dispensing of Study Drug.....</i>	<i>28</i>
5.7.4 <i>Return or Destruction of Study Drug.....</i>	<i>28</i>
6 STUDY PROCEDURES.....	28
6.1 PRE-ENTRY EVALUATIONS	28
6.2 ENROLLMENT AND BASELINE ASSESSMENT.	28
6.3 ENROLLMENT AND BASELINE ASSESSMENT.	29
6.4 APHERESIS #1.	29
6.5 CYTOREDUCTIVE CHEMOTHERAPY	29
6.6 RESTAGING ASSESSMENT.....	30
6.7 CART-19 INFUSION #1 WITH SPLIT DOSING	30
6.8 POST INFUSION LABORATORIES TO ASSESS ENGRAFTMENT AND PERSISTENCE.....	30
6.9 CART-19 INFUSION #2	31
6.10 DAY 28: APHERESIS #2	31
6.11 MONTHLY EVALUATIONS 2 TO 6 MONTHS POST INFUSION	31
6.12 QUARTERLY EVALUATIONS FOR UP TO 2 YEARS POST INFUSION.....	31
6.13 TUMOR RESPONSE ASSESSMENTS.....	32
7 STATISTICAL PLAN.....	32
7.1 GENERAL DESIGN ISSUES	32
7.2 ENDPOINTS.....	33
7.2.1 <i>Primary Endpoints</i>	<i>33</i>
7.2.2 <i>Secondary Endpoints.....</i>	<i>33</i>

7.3	SAMPLE SIZE.....	33
7.4	SAFETY.....	34
7.5	EFFICACY.....	34
7.6	ACCRUAL.....	34
7.7	SUBJECT POPULATION(S) FOR ANALYSIS.....	34
7.8	STATISTICAL ANALYSIS.....	35
8	SAFETY AND ADVERSE EVENTS.....	35
8.1	DEFINITIONS.....	35
8.2	RECORDING OF ADVERSE EVENTS.....	38
8.3	REPORTING OF SERIOUS ADVERSE EVENTS AND UNANTICIPATED PROBLEMS.....	38
8.3.1	<i>Study Sponsor Notification by Investigator.....</i>	<i>38</i>
8.3.2	<i>Investigator reporting: notifying the Penn IRB.....</i>	<i>39</i>
8.3.3	<i>Reporting obligations to the DSMC of the ACC.....</i>	<i>41</i>
8.3.4	<i>FDA Notification by Sponsor.....</i>	<i>41</i>
8.4	TOXICITY MANAGEMENT, STOPPING RULES AND STUDY TERMINATION.....	42
8.4.1	<i>Criteria for stopping or pausing the study.....</i>	<i>42</i>
8.4.2	<i>General toxicity management considerations.....</i>	<i>43</i>
8.4.3	<i>Management of toxicity.....</i>	<i>44</i>
8.4.4	<i>Criteria for discontinuing a subject's participation in the study:.....</i>	<i>44</i>
8.5	PROTOCOL DEVIATIONS.....	45
8.6	MEDICAL MONITORING.....	45
	<i>Independent Data and Safety Monitoring Board.....</i>	<i>45</i>
8.6.1	45
8.6.2	<i>Clinical Monitors.....</i>	<i>46</i>
9	DATA HANDLING AND RECORD KEEPING.....	46
9.1	CONFIDENTIALITY.....	46
9.2	SOURCE DOCUMENTS.....	47
9.3	CASE REPORT FORMS.....	47
9.4	RECORDS RETENTION.....	47
10	STUDY MONITORING, AUDITING, AND INSPECTING.....	47
10.1	STUDY MONITORING PLAN.....	47
10.2	AUDITING AND INSPECTING.....	48
11	ETHICAL CONSIDERATIONS.....	48
12	STUDY FINANCES.....	48
12.1	FUNDING SOURCE.....	48
12.2	CONFLICT OF INTEREST.....	48
12.3	SUBJECT STIPENDS OR PAYMENTS.....	49
12.4	STUDY DISCONTINUATION.....	49
13	PUBLICATION PLAN.....	49
14	REFERENCES.....	49
15	ATTACHMENTS.....	56
15.1	INFORMED CONSENT DOCUMENT.....	56
15.2	SCHEDULE OF STUDY PROCEDURES.....	72
15.3	PRODUCT C OF A, INFUSION FORM, AND DISPOSITION / RETURN FORMS.....	75
15.4	MONITORING PLAN.....	76

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.